3D Systems (DDD) announced that the U.S. Food and Drug Administration has granted 510(k) clearance expanding the indications for its VSP Orthopedics virtual surgical planning and patient-specific instrumentation platform to include skeletally mature adolescents of normal bone stature, in addition to adults.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DDD:
- 3D Systems Reduces Debt with Note Exchange Agreement
- 3D Systems announces $31M equitization transaction
- 3D Systems management to meet virtually with Needham
- 3D Systems: Hold Rating Amid Mixed Financial Performance and Market Challenges
- 3D Systems price target raised to $4.75 from $4 at Cantor Fitzgerald